Plain-English translation of NCT07123454 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called to see if it can help people with a type of blood cancer called B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatments. The study will look at whether the medication is safe, how the body processes it, and whether it actually helps shrink the cancer. Researchers are starting by testing different doses of the medication on its own to find the right amount and see how well it works.
Many people with advanced B-cell non-Hodgkin lymphoma run out of treatment options that actually work, especially after multiple rounds of therapy. This trial exists to see whether this new medication could offer hope to patients who have few other choices left.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive the new medication by mouth or injection at a study center, starting with dose escalation where doctors gradually increase the amount to find the right dose. You will have frequent visits early on to have blood work done, heart function checked, and scans to see if the cancer is responding. The study is designed to test safety and effectiveness, so your doctors will monitor you closely for any side effects and track how well the treatment is working over time.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States